enGene Therapeutics Inc

ENGN

Company Profile

  • Business description

    enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

  • Contact

    4868 Rue Levy
    Suite 220
    Saint-LaurentQCH4R 2P1
    CAN

    T: +1 514 332-4888

    https://www.engene.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 October 2027

    Employees

    82

Stocks News & Analysis

stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.
stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,997.30168.10-1.83%
CAC 408,246.31105.69-1.27%
DAX 4026,266.46332.18-1.25%
Dow JONES (US)51,608.17739.38-1.41%
FTSE 10010,744.36137.19-1.26%
HKSE23,508.17245.67-1.03%
NASDAQ24,509.76626.52-2.49%
Nikkei 22558,860.43801.59-1.34%
NZX 50 Index14,306.963.190.02%
S&P 5007,416.590.000.00%
S&P/ASX 2008,883.20161.50-1.79%
SSE Composite Index3,584.5817.99-0.50%

Market Movers